CIAN Agro (519477)
Fast GrowerScore breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹40.08 |
| Market Cap | ₹112.17 Cr |
| P/E Ratio | 21.69 |
| ROCE | 6.82% |
| ROE | 0.52% |
| Dividend Yield | 0% |
| Profit Growth | 173.51% |
| Debt/Equity | — |
| Sales Growth | 62.92% |
| 52-Week Range | ₹643.6 — ₹3,633.15 |
| Sector | Agricultural Food & other Products |
| Book Value | ₹34.68 |
Strengths
- Revenue grew 62.92%, and profit grew 173.51%, showing strong top-line and bottom-line momentum
- Piotroski F-Score of 7/9 indicates reasonably sound financial health
- Price-to-book of 1.16 with book value ₹34.68 provides a modest valuation cushion
- Latest quarter sales of ₹646 Cr and net profit of ₹90 Cr are impressive if sustainable
- PEG ratio of 0.18 suggests the growth is not fully reflected in the price
Concerns
- ROE is only 0.52%, meaning the company is generating negligible returns on shareholder equity
- ROCE of 6.82% is below typical cost of equity, raising questions about long-term value creation
- No dividend; zero yield offers no compensation while waiting for earnings to materialize
- 52-week range of ₹473.75 to ₹3,633.15 versus current price ₹40.08 is inconsistent and raises data-integrity red flags; promoter holding is N/A
AI Analysis
Looking at CIAN Agro, I am reminded that price and value often tell different stories. At ₹40.08, this edible oil company has a market cap of ₹112 Cr against a book value of ₹34.68, so the market is paying just 1.16 times book. That sounds reasonable until I see ROE of 0.52%—a fraction of what I expect from a quality business. The 62.92% sales growth and 173.51% profit growth are eye-catching, and a PEG of 0.18 suggests the market hasn't fully priced in the expansion. Latest quarter sales of ₹646 Cr and net profit of ₹90 Cr would be spectacular if annualized, but I cannot square that with a P/E of 21.69. Either the trailing earnings are depressed or the quarterly number is an outlier. The Piotroski score of 7 suggests decent financial health, but ROCE of 6.82% tells me the company still earns less than I could get from a simple index fund. There is no dividend to reward patient shareholders, and promoter holding is unknown—opacity is not my friend. The 52-week range of ₹473.75 to ₹3,633.15 with a current price of ₹40.08 is bizarre and signals possible data issues or corporate actions. As Graham said, the market is a voting machine in the short term, but the weighing machine in the long term. CIAN Agro may be growing fast, but fast growth with poor returns on capital often destroys value. I would demand clarity on earnings consistency, debt levels, and promoter skin in the game before committing capital. Extraordinary numbers invite extra scrutiny.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer